Sonnet BioTherapeutics Holdings Inc Stock

$4.73

20.66%

Nasdaq, Jul 07, 10:19 pm CET

ISIN

US83548R1059

Symbol

SONN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Sonnet BioTherapeutics Holdings Inc Stock price

$4.73

-8,496.07 99.94% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

+0.81 20.66%

ISIN

US83548R1059

Symbol

SONN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$12.4m

Enterprise Value

$10.4m

Net debt

positive

Cash

$2.1m

Shares outstanding

3.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

12.4 | 12.2

EV/Sales

10.4 | 10.1

EV/FCF

negative

P/B

18.5

Financial Health

Equity Ratio

-17.5%

Return on Equity

1,531.2%

ROCE

-2,056.9%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$1.0m | $1.0m

EBITDA

$-13.7m | $-46.2m

EBIT

$-13.8m | $14.8m

Net Income

$-13.3m | $-11.0m

Free Cash Flow

$-11.7m

Growth (TTM | estimate)

Revenue

900.0% | 5,000.0%

EBITDA

-7.9% | -292.6%

EBIT

-8.8% | -

Net Income

-57.7% | -48.0%

Free Cash Flow

12.3%

EPS

$-3.4

FCF per Share

$-3.7

Short interest

1.9%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Sonnet BioTherapeutics Holdings Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Sonnet BioTherapeutics Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	1 1	900% 900% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	8.08 8.08	42% 42% 808%
- Research and Development Expense	6.70 6.70	5% 5% 670%
EBITDA	-14 -14	8% 8% -1,366%
- Depreciation and Amortization	0.12 0.12	1,100% 1,100% 12%
EBIT (Operating Income) EBIT	-14 -14	9% 9% -1,378%
Net Profit	-13 -13	58% 58% -1,329%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Sonnet BioTherapeutics Holdings Inc Stock News

Neutral

GlobeNewsWire

●

2 months ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6 th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA.

Neutral

GlobeNewsWire

●

3 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010

Neutral

GlobeNewsWire

●

3 months ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ® )

More Sonnet BioTherapeutics Holdings Inc News

Company Profile

Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.

Head office	United States
CEO	Raghu Rao
Employees	13
Founded	2011
Website	www.sonnetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now